Top Story

Aflibercept for AMD largely maintains visual gains through 212 weeks

March 28, 2017

Vision gains achieved in the VIEW 1 trial were “largely maintained” at the conclusion of the VIEW 1 Extension Study, according to the study results.

In the four arms of the VIEW 1 trial, 1,217 patients with neovascular age-related macular degeneration were randomized to receive 0.5 mg intravitreal Eylea (aflibercept, Regeneron) injections every 4 weeks, 2 mg of aflibercept every 4 weeks, 2 mg of aflibercept every 8 weeks after three initial monthly doses, or 0.5 mg Lucentis (ranibizumab, Genentech) every 4 weeks. Mean best corrected visual acuity at baseline was 55.6 letters, and at the 96-week conclusion of the VIEW 1 trial, patients gained a mean of 10.2 letters.

IBM Watson, IDx collaborate on imaging applications

March 28, 2017
IBM Watson Health and IDx LLC announced a 5-year strategic alliance to advance eye health through cognitive computing applications to aid primary care providers…

BLOG: The HOMIE guide to MIGS

March 28, 2017
There’s no question that MIGS has become a worthwhile add-on to cataract surgery. The well-deserved amount of attention in journals and at meetings to these new…
In the Journals

Paid malpractice claims among US physicians declined significantly

March 28, 2017
Between 1992 and 2014, there was a significant decline in paid malpractice claims, possibly due to several factors, including the passage of traditional tort reforms…
The Premium Channel

Can the solo practice premium surgeon survive in today’s health care environment?

Ocular Surgery News U.S. Edition, April 10, 2017
Mitchell A. Jackson, MD
Twenty-four years ago, I was completing my third year of ophthalmology residency and already had plans to open a private practice solo in a somewhat rural location at…
More News Headlines »
Original Article

Visual, Topographic, and Pachymetric Effects of Pediatric Corneal Collagen Cross-linking

Journal of Pediatric Ophthalmology and Strabismus, March/April 2017, Volume 54 Issue 2
To evaluate the effects of pediatric corneal collagen cross-linking (CXL) on corrected distance visual acuity (CDVA)…
More »

Glaucoma: Novel Mechanisms and Treatments that Target the Elusive IOP

This activity is supported by an educational grant from Bausch + Lomb.

Glaucoma is currently the second leading cause of blindness throughout the world. The goal of glaucoma treatment is to…
More »
World Retina Congress

World Retina Congress

From OSN Europe Video
Meeting News

VIDEO: Astigmatism affects multifocal IOL models

February 20, 2017
More »